872624-52-7

Usage

Uses

Used in Organic Synthesis:
Methyl 2-amino-5-iodo-4-(trifluoromethyl)benzoate serves as a key intermediate in organic synthesis, where its functional groups can be selectively modified to produce a variety of complex organic molecules. The presence of the amino and ester groups, along with the iodine and trifluoromethyl substituents, allows for a broad spectrum of chemical reactions, facilitating the creation of diverse chemical entities.
Used in Medicinal Chemistry:
In the realm of medicinal chemistry, methyl 2-amino-5-iodo-4-(trifluoromethyl)benzoate is utilized as a precursor for the synthesis of novel drug candidates. Its unique structure and functional groups can be tailored to target specific biological pathways or receptors, potentially leading to the development of new therapeutic agents with improved efficacy and selectivity.
Used in Research Compounds:
Methyl 2-amino-5-iodo-4-(trifluoromethyl)benzoate also finds application as a research compound, where its introduction into various chemical and biological assays can provide insights into the structure-activity relationships of different classes of compounds. This can aid in the optimization of drug candidates and the understanding of molecular interactions at the molecular level.
Used in Pharmaceutical Development:
As a component in the development of pharmaceuticals, methyl 2-amino-5-iodo-4-(trifluoromethyl)benzoate can be incorporated into drug molecules to enhance their pharmacokinetic and pharmacodynamic properties. The iodine atom, in particular, can influence the lipophilicity and metabolic stability of the resulting compounds, while the trifluoromethyl group can impart specific biological activities or improve the drug's overall profile.

Upstream product

• 61500-87-6 methyl 2-Amino-4-(trifluoromethyl)benzoate 
• 320-94-5 2-nitro-4-trifluoromethylbenzoic acid 

Downstream Products

• 872624-91-4 2-amino-4-trifluoromethyl-5-vinyl-benzoic acid methyl ester 
• 872624-53-8 methyl 2-amino-5-methyl-4-trifluoromethylbenzoate 
• 912573-57-0 2-acetylamino-5-iodo-4-trifluoromethyl-benzoic acid methyl ester 
• 912574-18-6 2-amino-5-ethynyl-4-trifluoromethyl-benzoic acid methyl ester 
• 912574-17-5 2-amino-4-trifluoromethyl-5-trimethylsilanylethynyl-benzoic acid methyl ester 
• 912574-10-8 2-amino-5-(3-methoxy-prop-1-ynyl)-4-trifluoromethyl-benzoic acid methyl ester 
• 912574-26-6 2-amino-5-[5-methyl-2-(2-trimethylsilanylmethoxy-ethyl)-2H-pyrazol-3-yl]-4-trifluoromethyl-benzoic acid methyl ester 
• 912574-87-9 2-amino-5-(2-benzyloxy-2H-pyrazol-3-yl)-4-trifluoromethyl-benzoic acid methyl ester 
• 1427400-33-6 2-amino-5-iodo-4-(trifluoromethyl)benzoic acid 

Relevant academic research and scientific papers

Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease

Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel are established as the primary causative factor in the devastating lung disease cystic fibrosis (CF). More recently, cigarette smoke exposure has been shown to be asso

Design, synthesis and insecticidal activities of novel anthranilic diamides containing fluorinated groups as potential ryanodine receptors activitors

In order to search for novel potent and environmentally benign insecticides, a series of anthranilic diamides containing various fluorinated groups were designed and synthesized. Their structures were confirmed by 1H NMR, 13C NMR, s

Design and Synthesis of Selurampanel, a Novel Orally Active and Competitive AMPA Receptor Antagonist

A series of potent quinazolinedione sulfonamide antagonists of the α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor were designed and synthesized. The structure–activity relationships (SAR) and in vivo activity of the series were investigated. In particular, compound 1 S (selurampanel; N-[7-isopropyl-6-(2-methylpyrazol-3-yl)-2,4-dioxo-1H-quinazolin-3-yl]methanesulfonamide) has shown excellent oral potency against maximal electroshock seizure (MES)-induced generalized tonic–clonic seizures in rodents as well as significant activity in patients suffering from various forms of epilepsy. The X-ray crystal structure of selurampanel bound to the AMPA receptor hGluA was also obtained.

N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES

A compound of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, Ra, A, B, D and E are all as defined herein. The compounds modulate the activity of CFTR and are useful in

COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA

Compounds of Formula (I): wherein n, m, p, q, Y, R1 R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.

1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS

The present invention relates to l H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as AMPA-receptor ligands, in particular for the treatment of epilepsy or schizophrenia, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) and combinations comprising compounds of formula (I) are disclosed.